EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross‐Sectional Study

Adria Rose iD, Rohini R Datta iD, Costanza Di Chiara iD, Pierre-Philippe Piché-Renaud iD, Shaun K Morris iD

Pediatric Pulmonology · 2026-06 · 61 (6)

DOI: 10.1002/ppul.71696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 10.06.2026. Verfasst von Adria Rose und 4 weiteren Autor:innen. Beteiligte Einrichtung: Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Pediatricians, Health Knowledge, Attitudes, Practice, Attitude of Health Personnel. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Public Health Agency of Canada's Immunization Partnership Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

New RSV prevention products show strong potential, but their success depends on wide acceptance and use. We assessed Ontario pediatricians' knowledge and attitudes about these products before their introduction to highlight opportunities and barriers.

Methods

In March−April 2024, Pediatricians Alliance of Ontario newsletter subscribers ( n = 1566) were invited to complete an online survey on RSV knowledge and attitudes. Descriptive analyses with a complete‐case approach assessed responses.

Results

Of 117 responses (7% response rate), we retained 104 confirmed as from pediatricians with complete demographic data, including 81% (84/104) general pediatricians and 19% (20/104) subspecialists. Most worked in primary care (40%; 42/104), community hospitals (32%; 33/104), and urban centers (63%; 65/104), and had ≥ 10 years' experience (81%; 83/104). They had high awareness of provincial recommendations (91%; 94/103) and knowledge of severe RSV disease risk factors (Figure 2). While 83% (82/99) always recommended palivizumab to eligible patients, only 34% (34/99) reported that all eligible patients always received it. Over 90% were likely to recommend nirsevimab (91%; 89/98), but 66% (65/98) expected to administer it. Top anticipated barriers included the introduction of a new product (69%; 25/36) and concern for adverse effects (69%; 41/59). The likelihood of recommending a maternal vaccine over nirsevimab was 45% (44/98), while 44% (43/98) were neutral.

Conclusion

Ontario pediatricians were knowledgeable and supportive of RSV prevention products. However, they have experienced barriers with palivizumab, and they anticipated barriers with nirsevimab and the maternal RSV vaccine. As other jurisdictions look to implement new RSV prevention products, acknowledging and addressing anticipated barriers may promote acceptance and use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsPediatriciansHealth Knowledge, Attitudes, PracticeAttitude of Health PersonnelRespiratory Syncytial Virus VaccinesHumansCross-Sectional StudiesOntarioFemaleMaleAntiviral AgentsPalivizumabAdultSurveys and QuestionnairesMiddle AgedPractice Patterns, Physicians'

Stichwörter der Autor:innen

Canadabarriersimmunizationrespiratory syncytial virusvaccine

Substanzen

Antiviral AgentsPalivizumabRespiratory Syncytial Virus Vaccines

Autor:innen und Institutionen

  • Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Division of Infectious Diseases, The Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Adria Rose, Rohini R Datta, Costanza Di Chiara, Pierre-Philippe Piché-Renaud, Shaun K Morris

Förderung

  • Public Health Agency of Canada's Immunization Partnership Fund

Zitieren

APA

Rose, A., Datta, R. R., Di Chiara, C., Piché-Renaud, P. P., & Morris, S. K. (2026). Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross‐Sectional Study. Pediatric Pulmonology, 61(6). https://doi.org/10.1002/ppul.71696

Vancouver

Rose A, Datta RR, Di Chiara C, Piché-Renaud PP, Morris SK. Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross‐Sectional Study. Pediatric Pulmonology. 2026;61(6). doi:10.1002/ppul.71696

BibTeX
@article{Rose2026,
  author = {Rose, Adria and Datta, Rohini R and Di Chiara, Costanza and Piché-Renaud, Pierre-Philippe and Morris, Shaun K},
  title = {Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross‐Sectional Study},
  journal = {Pediatric Pulmonology},
  year = {2026},
  volume = {61},
  number = {6},
  doi = {10.1002/ppul.71696}
}
Kostenlos starten →